Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Launched by SAMSUNG MEDICAL CENTER · Jun 15, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how a medication called pembrolizumab affects patients with triple negative breast cancer who are receiving a specific type of chemotherapy before surgery. The researchers want to see how the treatment changes the tumor's environment in patients who do not achieve a complete response to the chemotherapy. Essentially, they are looking at whether adding pembrolizumab to the chemotherapy regimen can make a difference in how the tumor behaves and responds.

To participate in this trial, you need to have triple negative breast cancer and be receiving a combination of chemotherapy drugs, including weekly paclitaxel and carboplatin, followed by doxorubicin and cyclophosphamide, with or without pembrolizumab. You must also be planning to have surgery after your chemotherapy. This trial is open to all genders and includes adults aged 69 to 39 years. Participants will have the opportunity to contribute to important research that could help improve treatment options for others with this type of breast cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Triple negative breast cancer
• • Subjects administered neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide add Pembrolizumab or not
• • Non pCR patients who are undergoing surgery after neoadjuvant chemotherapy
• • Sign to informed consent
• Exclusion Criteria:
• • Patients with difficulty in obtaining sufficient samples